GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Forward PE Ratio

Sinco Pharmaceutical Holdings (HKSE:06833) Forward PE Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Forward PE Ratio?

Sinco Pharmaceutical Holdings's Forward PE Ratio for today is 0.00.

Sinco Pharmaceutical Holdings's PE Ratio without NRI for today is 9.83.

Sinco Pharmaceutical Holdings's PE Ratio for today is 10.26.


Sinco Pharmaceutical Holdings Forward PE Ratio Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Forward PE Ratio Chart

Sinco Pharmaceutical Holdings Annual Data
Trend
Forward PE Ratio

Sinco Pharmaceutical Holdings Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Sinco Pharmaceutical Holdings's Forward PE Ratio

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinco Pharmaceutical Holdings's Forward PE Ratio Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's Forward PE Ratio falls into.



Sinco Pharmaceutical Holdings Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sinco Pharmaceutical Holdings  (HKSE:06833) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sinco Pharmaceutical Holdings Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Traded in Other Exchanges
N/A
Address
No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.
Executives
Huang Zhijian 2305 Beneficiary of a trust
Fullwealth Holdings Limited 2201 Interest of corporation controlled by you
Risun Investments Limited 2101 Beneficial owner
Wickhams Cay Trust Company Limited 2301 Trustee
Huang Xiangbin 2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines